Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 60Neoplasms 41Carcinoma, Non-Small-Cell Lung 32Ovarian Neoplasms 27Neoplasm Metastasis 22Glioblastoma 19Lung Neoplasms 17Fallopian Tube Neoplasms 16Colonic Neoplasms 16Breast Neoplasms 16Rectal Neoplasms 15Pancreatic Neoplasms 15Carcinoma, Renal Cell 13Carcinoma, Hepatocellular 12Stomach Neoplasms 10Glioma 10Carcinoma, Ovarian Epithelial 8Solid Cancers 7Sarcoma 7Melanoma 7Liver Neoplasms 7Brain Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Solid Tumors 6Uterine Cervical Neoplasms 5Recurrence 5Lymphoma, Non-Hodgkin 5Astrocytoma 5Advanced Cancer 5Triple Negative Breast Neoplasms 4

Interventions

parsaclisib 2cemiplimab 2Midazolam 2MLN 8237 2Injections 2tanespimycin 1spartalizumab 1repaglinide 1epothilone B 1drospirenone 1cabiralizumab 1Pemetrexed 1Paclitaxel 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1MLN8054 1Ipilimumab 1Gemcitabine 1Ethinyl Estradiol 1Drug Therapy 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Malignancies × Bevacizumab × Clear all
NCT06717880 2025-02-12

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1 Recruiting
260 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡